|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||329.265 g/mol|
|(what is this?)|
AH-7921 is an opioid analgesic drug selective for the µ-opioid receptor, having around 80% the potency of morphine when administered orally. It was discovered in the 1970s by a team at Allen and Hanburys.
Dosages have been reported to range from as little as 10 mg to around 200 mg or higher (for opioid-tolerant individuals). This would confirm the previous studies of AH-7921 being roughly 80% as potent as morphine.
Although AH-7921 was extensively studied in vitro and in animals, though not in humans, by the developing company, it was never sold commercially for medical use. In 2013, AH-7921 was discovered to have been used as an active ingredient in "synthetic cannabis" products in Japan.
AH-7921 was made a Prohibited Substance (Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons) in Australia in May 2014. Although this amendment was repealed in June 2014, which simply means the amendment document ceases, but the actual scheduling is permanent as part of the main document (all SUSMP amendments cease after a few weeks). It may, however, still be a banned import.
AH-7921 has been illegal to distribute in Israel since December 2013.
In the UK, AH-7921 was included as a Class A drug under the 1971 Act in January 2015.
In Brazil, it's considered an illegal drug since May 2015 
- Brittain, R. T.; Kellett, D. N.; Neat, M. L.; Stables, R. (1973). "Proceedings: Anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides". British Journal of Pharmacology 49 (1): 158P–159P. doi:10.1111/j.1476-5381.1973.tb08279.x. PMC 1776456. PMID 4207044.
- Hayes, A. G.; Tyers, M. B. (1983). "Determination of receptors that mediate opiate side effects in the mouse". British Journal of Pharmacology 79 (3): 731–736. doi:10.1111/j.1476-5381.1983.tb10011.x. PMC 2044905. PMID 6317119.
- US patent 3975443, Harper, N.; Veitch, G., "1-(3,4-DICHLOROBENZAMIDOMETHYL)-CYCLOHEXYLDIMETHYLAMINE", issued 1976-08-17, assigned to Allen & Hanburys
- Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. doi:10.1007/s11419-013-0182-9.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|